| 1 |
14 |
ABCC9 (1.33, VLMC), B4GALNT1 (1.32, Glioblastoma (Cancer cells)), CNTN2 (1.43, Oligodendrocyte), FGFR3 (1.02, Astrocyte), GAD2 (1.03, Lamp5 Lhx6), IGFBP5 (1.1, Glioblastoma (Cancer cells)), NR4A2 (1.79, Glioblastoma (TME)), PLD5 (1.27, Pax6), RELN (1.47, Pax6), SDK1 (1.8, Chandelier), SPHKAP (1.31, Lamp5 Lhx6), TRAC (1.14, Glioblastoma (TME)), TRPC6 (1.39, Sst Chodl), UNC5B (1.14, Chandelier) |
| 2 |
12 |
FBLN1 (1.69, VLMC), NNAT (3.09, Glioblastoma (Cancer cells)), SOX11 (2.69, Glioblastoma (Cancer cells)), CUX2 (2.18, L2/3 IT), HS3ST4 (2.34, L6 CT), LRRK2 (2.47, OPC), NOTCH1 (1.58, Endothelial), RASGRP1 (1, L6 IT Car3), FSTL4 (1.55, L4 IT), SNCG (2.11, L5 ET), NRP1 (1.02, Endothelial), NPY1R (1.03, L6 IT Car3) |
| 3 |
16 |
BRINP3 (2.36, OPC), CENPF (1.93, Proliferation), LAMP5 (2.31, Lamp5 Lhx6), MEIS2 (1.88, Astrocyte), NDST4 (3.37, Sst Chodl), NTNG2 (1.44, L6 IT Car3), PAX6 (2.02, Astrocyte), PLCH1 (1.74, Sst), RFTN1 (1.83, VLMC), RORB (1.82, L4 IT), TENM1 (2.8, Chandelier), ANGPT1 (1.5, Pax6), PDGFD (1.03, Lamp5 Lhx6), ARHGAP24 (1.24, Microglia-PVM), IDH1 (1.26, Glioblastoma (Cancer cells)), CDH4 (1.13, Pax6) |
| 4 |
40 |
AIF1 (2.68, Glioblastoma (TME)), APOE (1.01, Microglia-PVM), C1orf162 (2.1, Glioblastoma (TME)), CD14 (2.94, Glioblastoma (TME)), CD163 (4.06, Glioblastoma (TME)), CD4 (2.37, Glioblastoma (TME)), CD68 (2.7, Glioblastoma (TME)), CD86 (2.17, Microglia-PVM), CORO1A (2.25, Glioblastoma (TME)), CTSH (1.58, Microglia-PVM), CTSS (2.68, Glioblastoma (TME)), CX3CR1 (3.09, Glioblastoma (TME)), FCER1G (2.85, Glioblastoma (TME)), FCGR1A (2.4, Glioblastoma (TME)), FCGR3A (3.1, Glioblastoma (TME)), GPR34 (3.18, Glioblastoma (TME)), HLA-DMB (2.6, Glioblastoma (TME)), HLA-DQA1 (2.67, Microglia-PVM), ITGAM (2.16, Microglia-PVM), ITGAX (2.89, Microglia-PVM), ITGB2 (3.22, Glioblastoma (TME)), LRRK1 (1.65, Microglia-PVM), LY86 (1.77, Glioblastoma (TME)), LYVE1 (2.98, Microglia-PVM), MS4A6A (3.31, Glioblastoma (TME)), P2RY12 (2.83, Microglia-PVM), P2RY13 (2.52, Microglia-PVM), PTPRC (2.34, Microglia-PVM), RGS10 (2.44, Glioblastoma (TME)), RNASET2 (2.4, Glioblastoma (TME)), SPI1 (2.79, Microglia-PVM), STXBP2 (1.31, Glioblastoma (TME)), TGFB1 (2.13, Microglia-PVM), TGFBI (2.98, Glioblastoma (TME)), TMIGD3 (2.64, Glioblastoma (TME)), TREM2 (2.81, Microglia-PVM), CXCR4 (1.58, Glioblastoma (TME)), GPR183 (1.21, Glioblastoma (TME)), CAPG (1.1, Glioblastoma (TME)), GPNMB (1.1, Glioblastoma (TME)) |
| 5 |
33 |
APOE (1.55, Microglia-PVM), BCAN (3.5, Glioblastoma (Cancer cells)), BRINP3 (1.24, OPC), CALCRL (1.31, OPC), CAV1 (1.23, Glioblastoma (Cancer cells)), CSPG4 (1.91, VLMC), ERBB3 (2.67, Oligodendrocyte), GAD1 (3.57, Pvalb), GPNMB (3.22, Glioblastoma (TME)), IGFBP3 (1.15, Glioblastoma (Cancer cells)), IGFBP4 (1.06, VLMC), ITGA8 (1.23, OPC), MOG (1.71, Oligodendrocyte), NES (2.07, Astrocyte), NTNG1 (2.67, Lamp5 Lhx6), OLIG1 (3.59, OPC), OLIG2 (3.75, OPC), PCSK1 (1.24, L5 ET), PDGFRA (4.26, OPC), PLCE1 (1.61, VLMC), POSTN (3.85, L6 IT Car3), PTCHD4 (1.26, Lamp5), PTPRZ1 (2.75, OPC), RIT2 (1.06, L5 ET), SEMA5A (3.21, OPC), SERPINA3 (2.38, VLMC), SORCS1 (3.21, L5 ET), SOX10 (4.26, OPC), STK32B (3.47, OPC), TMEM132C (2.04, VLMC), TTYH1 (1.05, Glioblastoma (Cancer cells)), UGT8 (3.04, Oligodendrocyte), VCAN (4.01, OPC) |
| 6 |
33 |
ANXA1 (1.92, Glioblastoma (Cancer cells)), CALCRL (3.47, OPC), CEMIP (3.69, VLMC), CEMIP2 (2.26, Endothelial), DCN (4.03, VLMC), FLT1 (4.14, Endothelial), IFITM3 (2.71, Microglia-PVM), IGFBP3 (3.52, Glioblastoma (Cancer cells)), IGFBP4 (3.98, VLMC), KLF2 (3.04, Glioblastoma (TME)), KLF4 (2.5, Glioblastoma (TME)), NES (1.8, Astrocyte), PECAM1 (4.15, Endothelial), PHLDB2 (2.28, VLMC), RNF144B (2.72, Endothelial), TGFBI (2.13, Glioblastoma (TME)), TGFB1 (1.78, Microglia-PVM), THSD4 (1.83, Endothelial), CAV1 (1.65, Glioblastoma (Cancer cells)), NRP1 (1.23, Endothelial), CDH6 (2.02, VLMC), HES1 (1.83, Glioblastoma (Cancer cells)), NOTCH1 (1.01, Endothelial), CD4 (1.46, Glioblastoma (TME)), LAMA2 (1.21, VLMC), THBS1 (2.18, Astrocyte), LYVE1 (1.24, Microglia-PVM), COL12A1 (1.33, VLMC), DDR2 (1.05, Pax6), SLIT3 (2.06, L5 ET), FILIP1 (1.22, L6 CT), ITGA8 (1.36, OPC), SNTB2 (1.08, L6 IT) |
| 7 |
30 |
ADRA1A (1.32, Sncg), ALK (1.47, Chandelier), APOE (2.06, Microglia-PVM), AQP4 (2.66, Astrocyte), BCAN (1.54, Glioblastoma (Cancer cells)), COL12A1 (2.38, VLMC), CRYM (1.45, L5/6 NP), EGFR (1.23, Glioblastoma (Cancer cells)), ELOVL2 (1.87, Glioblastoma (Cancer cells)), GJA1 (4.04, Astrocyte), HES1 (1.1, Glioblastoma (Cancer cells)), HHATL (1.26, Oligodendrocyte), IDH2 (1.01, Glioblastoma (Cancer cells)), NPNT (1.42, Chandelier), OLIG1 (1.91, OPC), OLIG2 (1.65, OPC), PTCHD4 (1.33, Lamp5), PTPRZ1 (2.29, OPC), RYR3 (3.1, Astrocyte), SEMA5A (1.66, OPC), SLC17A7 (2.2, L6b), SPON1 (3.73, Astrocyte), TGFB2 (1.96, Astrocyte), TRIL (3.5, Glioblastoma (Cancer cells)), TTYH1 (3.74, Glioblastoma (Cancer cells)), TSHZ2 (1.12, L5/6 NP), CCK (1.68, Pax6), PLCE1 (1.22, VLMC), LYPD6 (1.07, Lamp5 Lhx6), EYA4 (1.05, Lamp5 Lhx6) |
| 8 |
20 |
ANGPT1 (1.26, Pax6), BRINP3 (1.51, OPC), CHODL (2.86, Glioblastoma (Cancer cells)), CXCL14 (4.29, Pax6), CYTIP (1.8, Glioblastoma (TME)), GAD2 (1.42, Lamp5 Lhx6), LAMP5 (1.41, Lamp5 Lhx6), MEIS2 (1.1, Astrocyte), NDST4 (1.96, Sst Chodl), PAX6 (1.53, Astrocyte), RASGRP1 (1.84, L6 IT Car3), RGS16 (1.17, Microglia-PVM), SYNPR (3.38, Sst), TENM1 (1.47, Chandelier), VWC2L (2.49, L5/6 NP), MGST1 (1.15, Glioblastoma (Cancer cells)), NPY1R (1.16, L6 IT Car3), POU6F2 (1.52, L4 IT), FILIP1 (1.07, L6 CT), MAL (1.21, Oligodendrocyte) |
| 9 |
19 |
CCL5 (5.65, Glioblastoma (TME)), CD2 (4.48, Glioblastoma (TME)), CD3G (4.2, Glioblastoma (TME)), CD48 (3.58, Glioblastoma (TME)), CD52 (5.08, Glioblastoma (TME)), GZMA (5.06, Glioblastoma (TME)), IL7R (4.04, Glioblastoma (TME)), NKG7 (4.79, Glioblastoma (TME)), KLRB1 (3.32, Glioblastoma (TME)), TRAC (2.34, Glioblastoma (TME)), THEMIS (2.63, L6 IT Car3), S100A4 (2.7, Glioblastoma (TME)), CXCR4 (1.95, Glioblastoma (TME)), CYTIP (1.48, Glioblastoma (TME)), TESPA1 (1.83, L2/3 IT), PTPRC (1.6, Microglia-PVM), GNLY (2.15, Glioblastoma (TME)), CORO1A (1.94, Glioblastoma (TME)), IDO1 (1.19, Glioblastoma (TME)) |
| 10 |
16 |
ANXA1 (2.36, Glioblastoma (Cancer cells)), APOE (2.48, Microglia-PVM), AQP4 (1.96, Astrocyte), BCAN (1.22, Glioblastoma (Cancer cells)), GJA1 (1.17, Astrocyte), IFITM3 (1.29, Microglia-PVM), MGST1 (2.65, Glioblastoma (Cancer cells)), NES (1.27, Astrocyte), SERPINA3 (3.69, VLMC), SFRP2 (2.38, Pax6), TTYH1 (1.45, Glioblastoma (Cancer cells)), VCAN (1.01, OPC), CTSH (1.74, Microglia-PVM), SPON1 (1.02, Astrocyte), THBS1 (1.38, Astrocyte), POSTN (1.37, L6 IT Car3) |
| 11 |
57 |
KCNH5 (2.74, L6 CT), MYO5B (2.1, Pvalb), WIF1 (2.61, Pax6), ZBBX (2.87, L2/3 IT), MCTP2 (2.52, VLMC), ANKRD18A (2.59, Sst Chodl), ADAMTS12 (2.47, VLMC), IDO1 (2.56, Glioblastoma (TME)), VIP (2.47, Vip), FASLG (2.69, Microglia-PVM), OTOGL (2.6, L4 IT), NPFFR2 (2.91, L6b), LOX (2.2, Glioblastoma (Cancer cells)), MEPE (2.12, Pvalb), ANO3 (2.36, VLMC), CAV1 (2.26, Glioblastoma (Cancer cells)), TESPA1 (2.32, L2/3 IT), LYPD6B (2.15, Sncg), TPH2 (2.67, L5/6 NP), SLC17A6 (2.11, L4 IT), ADAMTS3 (2.38, L6 IT), CTNNA3 (2.44, Oligodendrocyte), ROS1 (2.13, L6b), RSPO2 (2.09, Pvalb), THEMIS (1.89, L6 IT Car3), CRHBP (2.02, Sst Chodl), CHODL (1.73, Glioblastoma (Cancer cells)), NWD2 (2.42, L6 IT Car3), POU6F2 (2.27, L4 IT), TRPC5 (1.84, L6 IT Car3), LHX6 (1.93, Chandelier), CDH12 (1.77, L6 IT Car3), SLC26A4 (1.71, L6 IT Car3), SAMD5 (2.32, Pvalb), CNTNAP3B (1.65, Chandelier), ADRA1B (2.24, Sncg), KLRB1 (1.67, Glioblastoma (TME)), NPY1R (1.61, L6 IT Car3), CD36 (1.38, L5/6 NP), OPALIN (1.71, Oligodendrocyte), ST18 (1.52, Oligodendrocyte), NXPH2 (1.55, Sst Chodl), GNLY (2.06, Glioblastoma (TME)), EYA4 (1.8, Lamp5 Lhx6), MOBP (1.3, Oligodendrocyte), HTR2A (1.67, L5 IT), NTNG1 (1.15, Lamp5 Lhx6), HTR2C (1.67, L5/6 NP), THSD4 (1.51, Endothelial), ANK1 (1.65, Chandelier), FILIP1 (1.67, L6 CT), PHLDB2 (1.49, VLMC), FSTL4 (1.47, L4 IT), SFRP2 (1.68, Pax6), VWC2L (1.4, L5/6 NP), IL7R (1.13, Glioblastoma (TME)), ADAMTS16 (2.01, L4 IT) |
| 12 |
12 |
B4GALNT1 (1.06, Glioblastoma (Cancer cells)), CCNB2 (3.04, Proliferation), CDK1 (2.43, Proliferation), MKI67 (2.54, Proliferation), TOP2A (2.34, Proliferation), TRPC6 (1.06, Sst Chodl), NR4A2 (1.17, Glioblastoma (TME)), GAS2L3 (2.46, L6 IT Car3), CENPF (1.76, Proliferation), SDK1 (1.5, Chandelier), KLK6 (1.22, Oligodendrocyte), CCNA1 (1.21, Proliferation) |
| 13 |
16 |
CCL4 (5.55, Microglia-PVM), CD83 (4.72, Glioblastoma (TME)), GPR183 (3, Glioblastoma (TME)), NR4A2 (1.43, Glioblastoma (TME)), ITGAX (1.68, Microglia-PVM), POSTN (1.59, L6 IT Car3), CD86 (1.73, Microglia-PVM), GPR34 (1.05, Glioblastoma (TME)), TREM2 (1.78, Microglia-PVM), FCGR1A (1.11, Glioblastoma (TME)), AIF1 (1.02, Glioblastoma (TME)), SPI1 (1.33, Microglia-PVM), CD68 (1.02, Glioblastoma (TME)), CD163 (1.29, Glioblastoma (TME)), TMIGD3 (1.08, Glioblastoma (TME)), CD14 (1.03, Glioblastoma (TME)) |
| 14 |
39 |
ADAMTS16 (3.38, L4 IT), ANO3 (2.4, VLMC), AQP4 (1.07, Astrocyte), C1QL3 (5.41, L6 IT), CCK (5.23, Pax6), CRYM (5.19, L5/6 NP), GJA1 (1.85, Astrocyte), HS3ST2 (4.22, L6 CT), PTPRZ1 (1.17, OPC), SLC17A7 (5.65, L6b), SLIT3 (4.24, L5 ET), TRIL (1.52, Glioblastoma (Cancer cells)), TSHZ2 (3.25, L5/6 NP), TTYH1 (1.71, Glioblastoma (Cancer cells)), OLIG1 (1.07, OPC), SLC17A6 (2.03, L4 IT), RXFP1 (2.87, L5 IT), SPON1 (1.44, Astrocyte), HTR2A (1.65, L5 IT), CDH12 (1.97, L6 IT Car3), ADRA1B (2.15, Sncg), PCSK1 (2.09, L5 ET), SNCG (1.64, L5 ET), COL12A1 (1.38, VLMC), RSPO2 (1.49, Pvalb), RYR3 (1.06, Astrocyte), CORO1A (1.27, Glioblastoma (TME)), CCNA1 (1.52, Proliferation), FSTL4 (1.4, L4 IT), SYNPR (1.39, Sst), TRHDE (1.98, Sst), ZDHHC23 (1.22, L6 IT Car3), NWD2 (1.41, L6 IT Car3), SORCS1 (1.05, L5 ET), RIT2 (1.2, L5 ET), HTR2C (1.35, L5/6 NP), ST18 (1.96, Oligodendrocyte), SAMD5 (1.03, Pvalb), ANK1 (1.27, Chandelier) |
| 15 |
4 |
KCNH5 (3.38, L6 CT), NPNT (2.52, Chandelier), RORB (1.95, L4 IT), APP (1.05, Broad) |
| 16 |
8 |
CCNB2 (4.24, Proliferation), CDK1 (4.09, Proliferation), CENPF (3.02, Proliferation), MKI67 (5.76, Proliferation), TOP2A (5.99, Proliferation), GAS2L3 (3.48, L6 IT Car3), PCNA (1, Proliferation), CCNA1 (2.07, Proliferation) |
| 17 |
15 |
CNDP1 (6.11, Oligodendrocyte), ERMN (4.86, Oligodendrocyte), MAG (6.12, Oligodendrocyte), MOBP (3.89, Oligodendrocyte), MOG (4.91, Oligodendrocyte), CAPN3 (3.42, Oligodendrocyte), OPALIN (3.19, Oligodendrocyte), UGT8 (3.06, Oligodendrocyte), CLDN11 (2.48, Oligodendrocyte), MAL (2.66, Oligodendrocyte), ST18 (2.28, Oligodendrocyte), KLK6 (2.73, Oligodendrocyte), MYRF (2.3, Oligodendrocyte), PCSK6 (1.59, Oligodendrocyte), HHATL (1.29, Oligodendrocyte) |
| 18 |
48 |
B4GALNT1 (1.28, Glioblastoma (Cancer cells)), MYO5B (1.7, Pvalb), NTNG2 (1.04, L6 IT Car3), FGFR2 (1, Oligodendrocyte), NR4A2 (1.01, Glioblastoma (TME)), TACR1 (2.16, Sst Chodl), SLC26A4 (2.2, L6 IT Car3), NXPH2 (2.16, Sst Chodl), LYPD6B (2.21, Sncg), SPHKAP (1.05, Lamp5 Lhx6), MEPE (1.75, Pvalb), CDH1 (2.02, Oligodendrocyte), MCTP2 (1.38, VLMC), CDH12 (1.69, L6 IT Car3), HHATL (1.58, Oligodendrocyte), KLK6 (1.95, Oligodendrocyte), WIF1 (1.38, Pax6), ANK1 (1.47, Chandelier), ANKRD18A (1.3, Sst Chodl), LHX6 (1.45, Chandelier), NWD2 (1.79, L6 IT Car3), ADRA1A (1.14, Sncg), TRPC5 (1.68, L6 IT Car3), SDK1 (1.61, Chandelier), IDO1 (1.37, Glioblastoma (TME)), SFRP2 (1.49, Pax6), MYRF (1.57, Oligodendrocyte), TPH2 (1.88, L5/6 NP), ST18 (1.36, Oligodendrocyte), ROS1 (1.69, L6b), LOX (1.3, Glioblastoma (Cancer cells)), PHLDB2 (1.1, VLMC), ZDHHC23 (1.86, L6 IT Car3), THSD7B (1.29, Sncg), FASLG (1.37, Microglia-PVM), THSD4 (1.17, Endothelial), ATP2C2 (1.77, L5/6 NP), FSTL4 (1.16, L4 IT), CTNNA3 (1.36, Oligodendrocyte), PCSK6 (1.03, Oligodendrocyte), TESPA1 (1.36, L2/3 IT), HTR2C (1.62, L5/6 NP), ADAMTS16 (1.58, L4 IT), CSPG4 (1.31, VLMC), NPFFR2 (1.23, L6b), RXFP1 (1.37, L5 IT), ZBBX (1.06, L2/3 IT), RIT2 (1.14, L5 ET) |
| 19 |
18 |
SST (6.81, Sst Chodl), TAC1 (6.51, Sst Chodl), PVALB (5.38, Chandelier), CRHBP (3.95, Sst Chodl), LHX6 (3.62, Chandelier), GAD1 (3.23, Pvalb), ANK1 (1.79, Chandelier), ALK (2.52, Chandelier), TRHDE (2.68, Sst), SYNPR (1.31, Sst), BTBD11 (1.22, Pvalb), SNCG (2.31, L5 ET), PCSK6 (1.22, Oligodendrocyte), TRPC5 (1.75, L6 IT Car3), NXPH2 (1.62, Sst Chodl), RSPO2 (1.35, Pvalb), KIT (1.89, Proliferation), SAMD5 (1.36, Pvalb) |
| 20 |
47 |
THBS1 (5.73, Astrocyte), SLC17A6 (3.97, L4 IT), PCSK1 (4.39, L5 ET), ALK (4.82, Chandelier), GAD1 (4.07, Pvalb), ANK1 (2.65, Chandelier), CALCRL (3.42, OPC), PLCE1 (3.68, VLMC), CORO1A (2.57, Glioblastoma (TME)), NPY1R (2.25, L6 IT Car3), CNTNAP3B (2.3, Chandelier), RIT2 (2.23, L5 ET), ADRA1A (2, Sncg), SAMD5 (2.43, Pvalb), CCNA1 (2.85, Proliferation), LYPD6 (1.9, Lamp5 Lhx6), CX3CR1 (1.75, Glioblastoma (TME)), NES (1.92, Astrocyte), CDH4 (1.75, Pax6), OLIG2 (1.28, OPC), IGFBP3 (2.06, Glioblastoma (Cancer cells)), PTPRZ1 (1.54, OPC), NTNG1 (2.11, Lamp5 Lhx6), TPH2 (1.46, L5/6 NP), AIF1 (1.61, Glioblastoma (TME)), SERPINA3 (1.15, VLMC), CD83 (1.17, Glioblastoma (TME)), FCGR3A (1.49, Glioblastoma (TME)), STAT3 (1.21, Endothelial), SNTB2 (1.38, L6 IT), ANXA1 (1.01, Glioblastoma (Cancer cells)), BCAN (1.28, Glioblastoma (Cancer cells)), P2RY12 (1.02, Microglia-PVM), HLA-DQA1 (1.17, Microglia-PVM), TREM2 (1.73, Microglia-PVM), SOX10 (1.34, OPC), TTYH1 (1.1, Glioblastoma (Cancer cells)), PSEN2 (1.08, Glioblastoma (Cancer cells)), HLA-DMB (1.15, Glioblastoma (TME)), ZDHHC23 (1.18, L6 IT Car3), SORCS1 (1.85, L5 ET), PTCHD4 (1.09, Lamp5), STK32B (1.95, OPC), LRRK1 (1.2, Microglia-PVM), LY86 (1.09, Glioblastoma (TME)), CCK (1.49, Pax6), SNCG (2.48, L5 ET) |
| 21 |
50 |
GPNMB (5.89, Glioblastoma (TME)), CD68 (2.88, Glioblastoma (TME)), TREM2 (3.13, Microglia-PVM), CTSS (3.09, Glioblastoma (TME)), PDGFRA (2.99, OPC), HLA-DMB (2.53, Glioblastoma (TME)), THBS1 (3.48, Astrocyte), MS4A6A (2.26, Glioblastoma (TME)), ANXA1 (2.68, Glioblastoma (Cancer cells)), APOE (2.21, Microglia-PVM), CD163 (2.43, Glioblastoma (TME)), CD48 (3.93, Glioblastoma (TME)), CEMIP (4.17, VLMC), CTSH (2.44, Microglia-PVM), FCER1G (1.71, Glioblastoma (TME)), HS3ST2 (3.7, L6 CT), CD4 (2.6, Glioblastoma (TME)), GPR34 (2.3, Glioblastoma (TME)), SOX10 (2.59, OPC), ITGAM (2.35, Microglia-PVM), AIF1 (2.22, Glioblastoma (TME)), VCAN (2.15, OPC), ITGB2 (2.96, Glioblastoma (TME)), IFITM3 (1.98, Microglia-PVM), CXCR4 (2.23, Glioblastoma (TME)), CAPG (2.84, Glioblastoma (TME)), ERBB3 (2.07, Oligodendrocyte), CD14 (2.47, Glioblastoma (TME)), IGFBP4 (2.84, VLMC), P2RY13 (1.94, Microglia-PVM), CD86 (1.48, Microglia-PVM), UGT8 (1.35, Oligodendrocyte), SORCS1 (2.87, L5 ET), SEMA5A (1.61, OPC), PLCE1 (1.02, VLMC), GAS2L3 (1.6, L6 IT Car3), LYVE1 (1.81, Microglia-PVM), NES (1.32, Astrocyte), POSTN (1.18, L6 IT Car3), DCN (2.24, VLMC), OLIG2 (1.52, OPC), HLA-DQA1 (2.32, Microglia-PVM), LY86 (1.09, Glioblastoma (TME)), PTPRC (1.82, Microglia-PVM), SERPINA3 (1.23, VLMC), CDH6 (2.09, VLMC), GPR183 (2.84, Glioblastoma (TME)), P2RY12 (1.93, Microglia-PVM), TGFBI (2.4, Glioblastoma (TME)), CCL4 (2.34, Microglia-PVM) |